뉴스벤징가
AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients
· 발표
기사 요약
AbbVie says nine-year CLL14 data showed longer progression-free survival with venetoclax plus obinutuzumab in chronic lymphocytic leukemia.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…